Hyperuricemia in psoriasis. Intersystem interrelationships and clinical significance

Background: Elevated serum uric acid levels are known to be a cause of a number of chronic diseases, including atherosclerosis, gout, nephritis, obesity, diabetes, and metabolic syndrome. Psoriasis is a chronic inflammatory disease with systemic manifestations that, according to recent studies, affects not only the skin and musculoskeletal system but is also accompanied by metabolic disorders.

Hyperuricemia is associated with severe psoriasis, the presence of psoriatic arthritis, and an increased risk of cardiovascular complications and gout. Despite increased scientific interest in this topic, the clinical significance of uric acid levels in patients with psoriasis remains unresolved.

Objective: Analytical Review of the scientific literature to identify a correlation between uric acid levels and the severity of psoriasis.

Conclusion: The results of this literature review indicate a relationship between hyperuricemia and psoriasis. This association is not limited to the presence of metabolic syndrome, but is evident in patients with psoriasis even in the absence of concomitant metabolic disorders due to accelerated cell turnover. Although elevated uric acid levels can be considered a potential biomarker of systemic inflammation, which characterizes the severity of psoriasis and associated pathologies, the limited number of large-scale studies hinders a definitive interpretation of the prognostic significance of this indicator. Nevertheless, the data obtained suggest that uric acid levels are not simply a marker, but rather an important pathogenetic factor reflecting the severity and chronicity of psoriasis, amplifying the inflammatory cascade through the activation of purine metabolism by cytokines. Further studies in larger cohorts of patients are needed to confirm these findings and clarify the prognostic role of hyperuricemia in psoriasis severity. Understanding the relationship between hyperuricemia and psoriasis may open new perspectives for the development of comprehensive therapeutic strategies aimed at correcting both skin manifestations and systemic metabolic disorders.